DNA mismatch repair protein gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png DNA mismatch repair protein gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-stage-ii-or-stage-iii-colorectal-cancer-not-eligible-for-oxaliplatin-chemotherapy/ Wed, 29 Apr 2026 15:00:33 +0000 https://clinicaltrials.eu/trial/study-on-atezolizumab-for-patients-with-high-risk-stage-ii-or-stage-iii-colorectal-cancer-not-eligible-for-oxaliplatin-chemotherapy/ This clinical trial is focused on studying a type of cancer called colorectal cancer, specifically in patients who have a high risk of recurrence or have stage III disease. These patients have tumors that are either MSI-high (microsatellite instability-high) or MMR-deficient (mismatch repair-deficient), which are specific characteristics of the cancer cells. The study is for those who cannot receive or choose not to receive a common chemotherapy treatment known as oxaliplatin. The main goal of the study is to see if a medication called atezolizumab, also known by its code name RO5541267, can help improve the chances of staying cancer-free for three years after treatment.

The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.

]]>